IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys
Tomas FM, Walton PE, Dunshea FR, et al. Journal of Endocrinology 1997;155:377-386.
What it found
The variants were 2-3 times more potent than IGF-1 at lowering blood sugar, and their effect lasted much longer: total sugar lowering over 4 hours was about 4-8 times greater. LR3 was the only variant that lowered plasma amino acids more than IGF-1.
Limitations
Single doses in pigs and marmosets. LR3 was tested only in pigs. The authors were exploring these variants as possible add-ons to insulin.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.